Nimble Therapeutics, Inc.

Company Announces Opening of a Second R&D site in Philadelphia, PA, and the Appointments of Shelley Allen as Head of Drug Discovery, and Munir Mosaheb as Head of Biology PHILADELPHIA--(BUSINESS WIRE)-- Nimble Therapeutics today announced the opening of a second R&D site in Philadelphia, PA. The new site, located in B+Labs, a hub for scientific innovation in University City Philadelphia, will focus on progressing Nimble’s growing pipeline of orally-delivered peptide therapeutics into clinical development. The Philadelphia site will synergize with activities at Nimble’s main R&D site in Madison, WI, which is focused on leveraging its proprietary platform to optimize oral peptide therapeutics at unprecedented scale and speed. In addition to the new site, Nimble also announced the appointment of two senior leaders to spearhead the drug discovery efforts and catalyze the build out of the Philadelphia site and team. Shelley Allen will join as Head of Drug Discovery and will lead the advanced optimization and characterization of clinical candidate peptides and their progression into the clinic. Munir Mosaheb will join as Head of Biology and will lead the pharmacological, immunological and translational aspects of Nimble’s drug discovery programs. Shelley has over 25 years of experience in the discovery and development of high-impact medicines. She joined Nimble from Think Bioscience where she was VP, Medicinal Chemistry, and responsible for establishing drug discovery teams and capabilities to develop their internal programs. Previously, Shelley spent 22 years with Array Biopharma / Pfizer in roles of increasing responsibility, contributing to the discovery of several clinical candidates including oncology therapeutics Vitrakvi® and Tukysa®. As director of medicinal chemistry at Pfizer, she led teams and programs from lead discovery to IND in the kinase space. Shelley began her career at Rhone-Poulenc Rorer after completing undergraduate studies at DeMontfort University of Leicester. She has published > 40 scientific papers and patents and is active in the American Chemical Society community. Munir has over 15 years of experience in developing and applying novel immunological insights in academic and biotech settings. Most recently Munir was the Head of Translational Biology and Immunology at Senda Biosciences (now Sail Biomedicines), where he built a Translational Biology team and led platform and program development, and IND-enabling preclinical data generation. Prior to Senda, Munir received broad training across diverse aspects of immunology. He explored molecular vaccinology during his time at Merck & Co. and the Wetzler lab at BU, studied T cell biology while at the Flavell lab at Yale, and immuno-oncology and cell trafficking as a post-doctoral fellow in the von Andrian lab at Harvard. "We are pleased to open our second R&D site in the Philadelphia area," said Jigar Patel, founder & CEO of Nimble Therapeutics. "This is a reflection of the growing maturity of our internal pipeline of orally-delivered peptide therapeutics, and the need to build additional capabilities as we progress candidates into the clinic.” “I’m thrilled to have Shelley and Munir join us at this exciting stage in the journey of Nimble,” said Pete Gough, CSO of Nimble Therapeutics. “They both bring a wealth of experience in the key areas of immunology, drug discovery and pre-clinical development and will be instrumental in building and leading the teams that will take our programs into the clinic.” "As a medicinal chemist of 25 years, I am incredibly impressed by the power and unprecedented speed of the Nimble platform to identify and optimize oral therapeutic peptides. I’m very much looking forward to partnering with our team in Madison to deliver a robust pipeline of clinical candidates to patients,” said Shelley. “Despite the progress we’ve made with parenteral biological therapies for the treatment of immune-mediated diseases over the past couple of decades, patients want oral medicines. Because of our platform, Nimble is uniquely placed to become a leader in developing oral peptide therapeutics as next-generation treatments for these patients and I’m excited to be part of the team to help this vision become reality,” said Munir. About Nimble Therapeutics Nimble is a biotechnology company dedicated to delivering on the promise of oral peptide therapeutics. Leveraging a paradigm-shifting peptide drug discovery and development engine, Nimble is advancing its internal pipeline and continues to support several partnered programs. The Nimble platform combines massively parallel solid-phase synthesis, unrivaled chemical and structural diversity, sophisticated assays, and powerful machine learning and computational methods. Nimble is located in Madison, WI and Philadelphia, PA. For more information, visit .

MADISON, Wis.--( BUSINESS WIRE )--Nimble Therapeutics announced that Dan Flynn and Brian Cali have joined the company’s Board of Directors. Both bring deep entrepreneurial and drug development track records that will guide Nimble as it continues to pursue its internal pipeline. Dr. Flynn has over 40 years of experience in the discovery and development of high-impact medicines. He recently retired from Deciphera Pharmaceuticals, a company he founded in 2003. At Deciphera, Dr. Flynn held positions of Chief Executive Officer, Executive Vice President, and Chief Scientific Officer where he oversaw the progression of several molecules through clinical trials, including Qinlock® for the treatment of gastrointestinal stromal tumors. Before founding Deciphera, Dr. Flynn held senior roles with various companies including Millennium Pharmaceuticals, Amgen Inc. and the Monsanto Company, G.D. Searle Unit. Dr. Flynn is currently Adjunct Professor of Medicinal Chemistry at the University of Kansas-Lawrence. He has served as the National Chair for the Division of Medicinal Chemistry of the American Chemical Society, is an American Chemical Society Fellow, and founder of the Bioorganic and Medicinal Chemistry Foundation. He is a member of the Board of Directors and Scientific Advisory Boards of several biotech companies. Dr. Flynn received both his B.S. in pharmacy and Ph.D. in medicinal chemistry from the University of Kansas and completed post-doctorate training in synthetic organic chemistry at Indiana University. Dr. Cali has over 25 years of pharma biotech experience. He co-founded Ironwood Pharmaceuticals in 1998 where he held leadership roles across R&D and corporate development and helped drive the company’s transformation from an early discovery stage startup to a commercial stage company with a market leading gastrointestinal (GI) disease product (Linzess ® ) and a diverse pre-commercial pipeline. Brian also led the investor engagement and financing efforts that enabled the creation of Cyclerion, an Ironwood spinout, in 2019. He currently serves on the Board of Directors of Jnana Therapeutics, a role he has held since 2018. He holds a B.S. from Cornell University, a Ph.D. in Cell and Molecular Biology from the University of Wisconsin-Madison and was a postdoctoral fellow at the Whitehead Institute. "We are pleased to welcome Daniel and Brian to our Board of Directors at this important stage of Nimble’s evolution," said Jigar Patel, founder & CEO of Nimble Therapeutics. "Both are renowned pharma biotech entrepreneurs, having founded and successfully led companies that have developed novel small molecule or peptide-based drugs. We look forward to their guidance as we work to bring breakthrough medicines into clinical development, and ultimately to patients in need.” "Daniel and Brian are valuable additions to Nimble’s board, and their expert guidance will be paramount to the company as it continues to concentrate on developing and progressing its internal pipeline,” said Board Chair Dan Zabrowski. “It is an exciting time to be joining Nimble as they seek to leverage their incredibly versatile technology and team to develop best-in-class / first-in-class peptide-based medicines for the treatment of important diseases.” said Dr. Flynn. “Nimble has a paradigm shifting platform and I am impressed with what they have already accomplished. I look forward to helping the company as their efforts toward their own pipeline intensify, and they push towards the clinic and beyond.” said Dr. Cali. About Nimble Therapeutics Nimble is a biotechnology company dedicated to delivering on the promise of peptide therapeutics. Leveraging a paradigm-shifting peptide drug discovery and development engine, Nimble is advancing its internal pipeline and continues to support several partnered programs. The Nimble platform combines massively parallel solid-phase synthesis, unrivaled chemical and structural diversity, sophisticated assays, and powerful machine learning and computational methods. Nimble is located in Madison, WI and Philadelphia, PA. For more information, visit www.nimbletherapeutics.com .

▎药明康德内容团队编辑近日，利用下一代肽发现平台来识别难以成药靶点的药物的生物技术公司Nimble Therapeutics宣布，其与罗氏（Roche）旗下的基因泰克（Genentech）公司扩大了合作，并签署了一项许可协议，以开发用于多个疾病治疗领域的肽疗法。Nimble的官网信息显示，Nimble颠覆性的肽药物发现和开发引擎能够基于其大规模、具有化学上的多样性的氨基酸库为每个靶点根据其属性设计量身定制的文库，其化学空间的设计灵活且广阔。此外，该平台能够进行定制文库的精细组合合成，几个小时内就能合成多达数百种不同的线性环状和支链构象单体。然后通过大规模平行筛选和优化，以及其集成了生物信息学、化学信息学和机器学习的分析技术，Nimble能够高效、智能地发现和开发下一代肽疗法。根据此次与基因泰克合作协议的条款，Nimble将获得2000万美元的预付款。此外，Nimble还有望获得超过11亿美元的近期、临床前、临床和商业里程碑付款，以及分级特许权使用费。Nimble将使用其平台针对多种靶点识别潜在的化合物，基因泰克和罗氏将负责临床前和临床开发，以及最终产品的商业化。据Nimble此前的新闻稿，该公司已与多家医药公司建立了药物开发合作伙伴关系，其平台经广泛验证，为多个项目提供了具有高生物活性的化合物，涵盖多种治疗靶点类别。2022年12月，Nimble为一家大型医药公司合作的两个项目提供了先导化合物，获得了里程碑付款。而在此前的9个月中，Nimble已向其合作伙伴提供了4个项目的先导化合物。图片来源：123RFNimble Therapeutics的创始人兼首席执行官Jigar Patel博士表示：“我们很高兴能够扩大和加强我们与基因泰克的合作伙伴关系。基因泰克一直是一个有价值的战略合作伙伴。我们迄今为止的成功使我们有机会拓展与基因泰克和罗氏的合作，这令我们感到自豪。”“与基因泰克扩大的合作伙伴关系，以及我们近期在所有合作项目中取得的多个里程碑证明了Nimble提供肽候选药物的能力，”Nimble Therapeutics的首席战略官Pete Gough博士说道，“我们很高兴能够与基因泰克合作，进一步利用我们的差异化平台针对一大批新靶点加速开发优化的候选药物。”罗氏制药合作伙伴全球负责人James Sabry博士表示：“鉴于我们最初合作取得的成功，我们期待深化与Nimble的合作伙伴关系，在各个疾病领域共同应对大量重要且具有挑战性的靶点。”药明康德为全球生物医药行业提供一体化、端到端的新药研发和生产服务，服务范围涵盖化学药研发和生产、生物学研究、临床前测试和临床试验研发、细胞及基因疗法研发、测试和生产等领域。如您有相关业务需求，欢迎点击下方图片填写具体信息。▲如您有任何业务需求，请长按扫描上方二维码，或点击文末“阅读原文/Read more”，即可访问业务对接平台，填写业务需求信息▲欲了解更多前沿技术在生物医药产业中的应用，请长按扫描上方二维码，即可访问“药明直播间”，观看相关话题的直播讨论与精彩回放参考资料：[1] Nimble Therapeutics Announces Expansion of its Discovery and Development Partnership with Genentech. Retrieved January 6, 2023, from https://nimbletherapeutics.com/nimble-therapeutics-announces-expansion-of-its-discovery-and-development-partnership-with-genentech/[2] Nimble Therapeutics Delivers Lead Compounds for Two Programs Under Collaboration with Large Pharma Partner, Triggering Milestone Payments. Retrieved January 6, 2023, from https://nimbletherapeutics.com/nimble-therapeutics-delivers-lead-compounds-for-two-programs-under-collaboration-with-large-pharma-partner-triggering-milestone-payments/免责声明：药明康德内容团队专注介绍全球生物医药健康研究进展。本文仅作信息交流之目的，文中观点不代表药明康德立场，亦不代表药明康德支持或反对文中观点。本文也不是治疗方案推荐。如需获得治疗方案指导，请前往正规医院就诊。版权说明：本文来自药明康德内容团队，欢迎个人转发至朋友圈，谢绝媒体或机构未经授权以任何形式转载至其他平台。转载授权请在「药明康德」微信公众号回复“转载”，获取转载须知。分享，点赞，在看，聚焦全球生物医药健康创新